RXO · RXO, Inc. · Stock research

Current Thesis

The binary resolved and the equity did not re-rate. RXO reported Q2 2026 before the open on 2026-08-06: revenue $1.774B against $1.603B consensus, adjusted EPS $0.06 against $0.03, and adjusted EBITDA of $40M — above the top of the $27–37M guide the prior note called the whole argument. The next day they took back $21.70, +7.21% on 2,004,690 shares, on a single upgrade.

What the market re-priced on the beat was the balance sheet. At 2026-06-30 total debt was $506M against $15M of cash, net debt $491M, LTM gross leverage 4.2x and net leverage 4.1x bank-adjusted EBITDA, with $350M of available liquidity and a $200M ABL accordion. Adjusted free cash flow was negative $42M, driven by $70M of working-capital usage as freight rates rose and carrier QuickPay utilisation increased. That is the mechanism of an asset-light broker in an up-cycle: the cycle consumes cash before it produces earnings.

The sell-side response on 2026-08-07 was four target cuts and one upgrade. TD Cowen kept Sell and went to $17.50 from $19; UBS held Neutral at $23; Citigroup held Neutral at $23, down from the $30 it set on 2026-07-09; Truist held Buy but cut to $28 from the $30 it raised to on 2026-07-15; Citizens upgraded to Market Outperform with a $30 target. A quarter that beat its own guide produced a lower average target.

The prior note's structural level is gone. The $24 weekly shelf flagged there gave way in the week ended 2026-07-31, which closed $20.25. The name has since traded a $20.24–$22.13 closing band. The frame that matters now is whether a base holds above the print-day low while the cycle data keeps running hot and the liability question stays unquantified beyond one disclosure.

Bullish and bearish views on RXO, Inc.

The model's bull view on RXO, Inc. (RXO), in brief: Q2 adjusted EBITDA $40M beat the $27–37M guide and exceeded the $38M earned in Q2 2025 — the first year-over-year EBITDA growth of this cycle, on revenue of $1.774B versus $1.42B a year earlier (Q2 2026 release, 2026-08-06). The bear view: Leverage moved the wrong way through the beat. Both cases follow in full.

Bull Case

• Q2 adjusted EBITDA $40M beat the $27–37M guide and exceeded the $38M earned in Q2 2025 — the first year-over-year EBITDA growth of this cycle, on revenue of $1.774B versus $1.42B a year earlier (Q2 2026 release, 2026-08-06).
• Truckload gross profit per load rose 11% sequentially, the fastest in four years, with spot mix up roughly 900bps sequentially to 42% and pricing growth at a five-year high (Q2 2026 presentation, 2026-08-06). This is the operating-leverage mechanism the cyclical case required, showing up as a measured number rather than a projection.
• Truckload volume grew 2% YoY, which management framed as profitable share gain achieved ahead of schedule (Q2 2026 call, 2026-08-06).
• The Q3 2026 guide is adjusted EBITDA $35–45M, with brokerage volume growth guided to low-to-mid single digits YoY and truckload gross profit per load up sequentially again (2026-08-06).
• The spot backdrop remains far above trend. DAT's dry van report published in early August 2026 put spot linehaul at $2.32/mile, +42.1% YoY and 30.0% above the nine-year seasonal average of $1.78, with the load-to-truck ratio at 10.93 versus 9.92 the prior week and 6.64 a year earlier. Truck posts fell 12.5% week over week and 27.8% YoY — capacity leaving faster than freight.
• Insurance exposure got its first public number. CFO Jamie Harris put annual casualty insurance spend at approximately $15–20M with a $5M deductible per occurrence, and said RXO expects renewal increases meaningfully better than the industry given its claims history and vetting standards (Q2 2026 call, 2026-08-06). Until that call, no RXO figure existed against the post-Montgomery liability question.

Bear Case

• Leverage moved the wrong way through the beat. Net leverage 4.1x bank-adjusted at 2026-06-30 against 3.7x reported for Q1 2026, cash down to $15M from $21M, liquidity $350M versus $386M. Management expects the ratio to decline by year-end as EBITDA scales; that is guidance, not a result.
• Gross margin keeps compressing. Q2 2026 gross margin was $247M, 13.9% of revenue, against $252M and 17.8% in Q2 2025 — a lower dollar figure on 25% more revenue. Q1 2026 was 14.2% versus 16.0% a year earlier. Whether this is spot-cycle timing or shipper-side structural pressure is the argument the February 2026 session, in which RXO fell 20.45%, priced violently in one direction.
• Negative $42M adjusted free cash flow in the quarter, on $70M of working-capital usage. A faster recovery consumes more working capital, so the bull case and the cash-burn case share a driver.
• Targets fell on a beat. The 2026-08-07 cluster left the published range roughly $17.50 (TD Cowen) to $35 (BMO, initiated 2026-07-14) — dispersion that measures an unresolved argument rather than a settled view.
• The legal benchmark is still uncertified. The $604M Dallas County verdict in Lipe v. Lupus Superior (2026-07-23/24) reached C.H. Robinson through a borrowed-employee vicarious-liability finding, running past its 23% apportioned share; C.H. Robinson has said it will appeal. RXO is not a party, and is being discounted against it anyway.
• Spot momentum is easing at the margin. Dry van linehaul fell 2.4% week over week to $2.32 in the early-August DAT print, after a 2.5% weekly decline to $2.38 in the week ended 2026-07-24.

Setup & Price Structure

Closing tape into 2026-08-07: $22.64 on 07-28 (-6.10%, TD Cowen downgrade to Sell), $22.29 on 07-29, $20.57 on 07-30 (-7.72% on 3,605,380 shares), $20.25 on 07-31, $20.74 on 08-03, $22.13 on 08-04 (+6.70%), $21.00 on 08-05 (-5.11%), $20.24 on 08-06 (print day, -3.62%), $21.70 on 08-07 (+7.21%). Market cap $3.58B. The 52-week range is $10.43–$29.90, with the high set 2026-07-21.

Structurally: the May–June breakout shelf broke on the weekly close of 2026-07-31. What exists now is nine sessions of chop between a $20.24 closing floor and a $22.64 ceiling, with the print absorbed inside it. There is no reclaim of the pre-downgrade level and no lower low since 08-06. Six of the last ten sessions moved more than 3%, three of them more than 6% — realised volatility consistent with the roughly 1.9 beta the name has carried.

Narrative life-cycle: SATURATED. Dating it: 21 analysts cover the name per S&P Global (as of 2026-07-28); the entire sell-side catch-up landed in eight sessions between 2026-07-09 and 2026-07-16; the 52-week high printed 2026-07-21; the first downgrade came 2026-07-28; and five separate houses acted on one day, 2026-08-07, four of them cutting, on a quarter that beat its guide. Coverage arrived at the top, the bid did not follow, and a genuine upside surprise bought one session of gain. That is a well-known story with a thin marginal buyer. The share count barely moved while days-to-cover jumped, meaning average volume thinned. The 2026-08-06 close sat below the declining 20-day, with the July 21 high roughly a third above the print-day close. Retail-facing coverage clustered on the beat headline (Benzinga pre-market movers list, 2026-08-06) on the same day the stock closed red. The earnings date is now behind rather than ahead, which removes the single event that had been suppressing new positioning; no insider-sale or issuance datapoint has been disclosed since the print.

Catalyst Calendar (next 30 days)

• 2026-08-10 (est.) — weekly DAT dry van report for the following week. Tests whether the $2.32/mile print extends a second consecutive weekly decline or stabilises with the load-to-truck ratio above 10.
• 2026-08-11 — Chief Strategy Officer Jared Weisfeld presents at the Deutsche Bank Chicago Industrials Summit, 5:00 p.m. EDT, webcast (announced 2026-08-03). First forum after the print for anything management did not quantify on the call.
• ~2026-08-11 (est.) — FINRA short-interest data for the 2026-07-31 settlement. Reads whether the 9.05%-of-float short base was added to or covered through the pre-print drawdown.
• 2026-08-14 — Q2 2026 13F deadline.
• ~2026-08-19 (est.) — RXO Curve Q2 2026 truckload spot-rate report. The Q1 edition (published 2026-05-20) showed index 129, +16.5% YoY, and guided to a larger Q2 growth rate.
• ~2026-08 to 2026-09 (est.) — post-trial proceedings in Lipe v. Lupus Superior, Dallas County. Whether the court enters, reduces or vacates the ~$604M verdict sets the benchmark the broker cohort is discounted against.

What Would Change Our Mind

The structure already broke once: the $24 weekly shelf named in the prior note failed on the 2026-07-31 close of $20.25, and the beat did not repair it. The question is now whether the $20.24 print-day floor holds. A weekly close below $20 removes the post-print base and leaves no reference level between there and the $10.43 low of the past year.

On fundamentals, the case breaks if Q3 adjusted EBITDA lands below the $35–45M guided range, or if the Q3 balance sheet shows net leverage above the 4.1x reported for 2026-06-30 with adjusted free cash flow negative for a second straight quarter — that would establish the up-cycle as cash-consumptive rather than deleveraging. On the cycle, DAT dry van spot extending consecutive weekly declines from $2.32/mile toward the $1.78 nine-year seasonal average, or an RXO Curve Q2 reading below the Q1 +16.5% YoY, removes the offset to the liability discount.

The upside case would be re-established by a weekly close above $22.64 (the 2026-07-28 pre-downgrade level) with Q3 gross margin rising sequentially from 13.9% — the combination that would separate cyclical margin timing from structural compression. A quantified insurance renewal at or near the existing $15–20M annual casualty spend, disclosed at the 2026-08-11 conference or the Q3 print, would do the same for the legal overhang.

Correlation Notes

• C.H. Robinson is the read-through vehicle for legal risk, not for operations. RXO fell 6.10% on 2026-07-28, the session TD Cowen downgraded it citing a likely wave of broker lawsuits inflating insurance premiums, five days after the Dallas verdict against a company RXO has no interest in. Any post-trial ruling in Lipe moves the cohort together.
• DAT weekly dry van data and the RXO Curve index drive the cyclical leg, and they can diverge from the equity: spot ran +45.6% YoY in the week to 2026-07-24 while the stock fell through its base in the same window.
• High beta near 1.9 amplifies index and industrials moves in both directions. The reference session is February 2026, when RXO fell 20.45% on a structural-margin scare, and the 07-30 and 08-05 sessions (-7.72%, -5.11%) show the same character on smaller catalysts.
• The truckload-brokerage complex — CHRW, LSTR, JBHT's ICS unit, plus RXO — shares the post-Montgomery liability discount, so a cohort-wide re-rating can move RXO without any RXO-specific news.
• the mix with the most spot leverage and the most litigation exposure, which is why the cyclical and legal legs of this name are not independent.